Does the media favor MIRM or ROIV?

In the previous week, Roivant Sciences had 6 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 15 mentions for Roivant Sciences and 9 mentions for Mirum Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.29 beat Mirum Pharmaceuticals' score of 0.96 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or VTRS?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 4 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 0.96 beat Viatris' score of 0.77 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or MIRM?

In the previous week, Moderna had 14 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Moderna and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.96 beat Moderna's score of 0.45 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or GMAB?

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Mirum Pharmaceuticals' score of 0.96 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or ASND?

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 9 mentions for Mirum Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.32 beat Mirum Pharmaceuticals' score of 0.96 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mirum Pharmaceuticals (MIRM) Competitors

$94.00 -1.48 (-1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$93.99 -0.01 (-0.01%)

As of 05:20 PM Eastern

Compare

MIRM vs. ROIV, VTRS, MRNA, GMAB, and ASND

Should you buy Mirum Pharmaceuticals stock or one of its competitors? MarketBeat compares Mirum Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mirum Pharmaceuticals include Roivant Sciences (ROIV), Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Mirum Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.00	-$23.36M	-$13.61	N/A
Roivant Sciences	$8.26M	2,473.91	-$299.77M	-$0.60	N/A

Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals presently has a consensus price target of $137.64, suggesting a potential upside of 46.43%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential upside of 18.24%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Roivant Sciences had 6 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 15 mentions for Roivant Sciences and 9 mentions for Mirum Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.29 beat Mirum Pharmaceuticals' score of 0.96 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to Roivant Sciences' net margin of -3,629.19%. Mirum Pharmaceuticals' return on equity of -11.28% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Summary

Mirum Pharmaceuticals beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Viatris?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.00	-$23.36M	-$13.61	N/A
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 4 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 0.96 beat Viatris' score of 0.77 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris has a net margin of -2.04% compared to Mirum Pharmaceuticals' net margin of -140.24%. Viatris' return on equity of 19.04% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Viatris	-2.04%	19.04%	7.62%

79.9% of Viatris shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mirum Pharmaceuticals currently has a consensus target price of $137.64, indicating a potential upside of 46.43%. Viatris has a consensus target price of $17.50, indicating a potential upside of 10.97%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Mirum Pharmaceuticals beats Viatris on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Moderna had 14 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Moderna and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.96 beat Moderna's score of 0.45 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to Moderna's net margin of -143.55%. Mirum Pharmaceuticals' return on equity of -11.28% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has lower revenue, but higher earnings than Moderna. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.39	-$2.82B	-$8.15	N/A
Mirum Pharmaceuticals	$521.31M	11.00	-$23.36M	-$13.61	N/A

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Moderna presently has a consensus target price of $36.60, indicating a potential downside of 20.42%. Mirum Pharmaceuticals has a consensus target price of $137.64, indicating a potential upside of 46.43%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Genmab A/S?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Genmab A/S has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.00	-$23.36M	-$13.61	N/A
Genmab A/S	$3.72B	4.10	$963M	$1.32	18.55

7.1% of Genmab A/S shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S has a net margin of 21.05% compared to Mirum Pharmaceuticals' net margin of -140.24%. Genmab A/S's return on equity of 15.34% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Genmab A/S	21.05%	15.34%	8.94%

Mirum Pharmaceuticals currently has a consensus target price of $137.64, suggesting a potential upside of 46.43%. Genmab A/S has a consensus target price of $37.93, suggesting a potential upside of 54.87%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Mirum Pharmaceuticals' score of 0.96 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Mirum Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Ascendis Pharma A/S has a net margin of 57.87% compared to Mirum Pharmaceuticals' net margin of -140.24%. Ascendis Pharma A/S's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Mirum Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.00	-$23.36M	-$13.61	N/A
Ascendis Pharma A/S	$814.57M	16.07	-$258M	$8.67	24.20

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 9 mentions for Mirum Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.32 beat Mirum Pharmaceuticals' score of 0.96 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals presently has a consensus price target of $137.64, indicating a potential upside of 46.43%. Ascendis Pharma A/S has a consensus price target of $295.39, indicating a potential upside of 40.80%. Given Mirum Pharmaceuticals' higher probable upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mirum Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Mirum Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.73B	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-6.91	18.99	24.46	23.62
Price / Sales	11.00	290.48	500.50	105.27
Price / Cash	1,835.75	118.24	42.36	56.09
Price / Book	15.36	8.00	10.43	6.70
Net Income	-$23.36M	$23.89M	$3.56B	$337.26M
7 Day Performance	2.14%	-3.49%	-1.39%	-1.41%
1 Month Performance	-12.28%	1.03%	0.86%	1.15%
1 Year Performance	91.92%	34.39%	19.42%	22.61%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	3.8959 of 5 stars	$94.00 -1.6%	$137.64 +46.4%	+102.9%	$5.73B	$521.31M	N/A	140	Analyst Upgrade Insider Trade
ROIV Roivant Sciences	2.9084 of 5 stars	$28.70 +1.6%	$33.59 +17.0%	+162.2%	$20.32B	$8.26M	N/A	860	Positive News
VTRS Viatris	3.1636 of 5 stars	$15.56 -0.8%	$16.43 +5.6%	+83.9%	$18.27B	$14.30B	N/A	30,000
MRNA Moderna	1.3206 of 5 stars	$49.06 +7.5%	$35.73 -27.2%	+69.6%	$18.11B	$1.94B	N/A	4,700	Analyst Forecast Insider Trade
GMAB Genmab A/S	4.4615 of 5 stars	$23.88 +0.1%	$37.93 +58.8%	+12.8%	$14.87B	$3.72B	18.09	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. ROIV, VTRS, MRNA, GMAB, and ASND

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Summary

How does Mirum Pharmaceuticals compare to Moderna?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Summary

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. ROIV, VTRS, MRNA, GMAB, and ASND

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Which has stronger valuation & earnings, MIRM or ROIV?

Which has more risk and volatility, MIRM or ROIV?

Do insiders and institutionals hold more shares of MIRM or ROIV?

Do analysts recommend MIRM or ROIV?

Does the media favor MIRM or ROIV?

Is MIRM or ROIV more profitable?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Which has more volatility & risk, MIRM or VTRS?

Which has higher earnings & valuation, MIRM or VTRS?

Does the media refer more to MIRM or VTRS?

Is MIRM or VTRS more profitable?

Do insiders & institutionals hold more shares of MIRM or VTRS?

Do analysts rate MIRM or VTRS?

Summary

How does Mirum Pharmaceuticals compare to Moderna?

Does the media favor MRNA or MIRM?

Is MRNA or MIRM more profitable?

Which has more risk and volatility, MRNA or MIRM?

Which has better earnings and valuation, MRNA or MIRM?

Do institutionals and insiders believe in MRNA or MIRM?

Do analysts rate MRNA or MIRM?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Which has stronger valuation and earnings, MIRM or GMAB?

Do insiders & institutionals have more ownership in MIRM or GMAB?

Is MIRM or GMAB more profitable?

Do analysts prefer MIRM or GMAB?

Which has more risk and volatility, MIRM or GMAB?

Does the media refer more to MIRM or GMAB?

Summary

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Is MIRM or ASND more profitable?

Which has better valuation and earnings, MIRM or ASND?

Does the media prefer MIRM or ASND?

Do analysts recommend MIRM or ASND?

Which has more volatility & risk, MIRM or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools